Enstilar (Betamethasone Dipropionate, Calcipotriol Monohydrate)

Enstilar is indicated for the topical treatment of specific psoriasis manifestations.

• Plaque psoriasis affecting the trunk, limbs, or other body sites, particularly when lesions are thin to moderately thick.
• Scalp psoriasis, providing coverage of hair‑bearing areas without leaving a heavy residue.
• Adjunctive use with other prescribed topical treatments, such as moisturizers or keratolytics, when a combined approach is clinically appropriate.
• Short‑term maintenance after successful clearance to help prevent recurrence in previously affected areas.

Side‑effects reported with Enstilar are generally mild, but serious reactions can occur.

Common

• Mild skin irritation or burning at the application site.
• Pruritus (itching).
• Dryness or flaking of the treated skin.
• Transient erythema.

Serious

• Signs of skin atrophy such as thinning or bruising.
• Development of secondary bacterial, fungal, or viral infections.
• Allergic contact dermatitis.
• Systemic corticosteroid effects (e.g., adrenal suppression) with extensive use.

Before using Enstilar, consider the following precautions to ensure safe and effective therapy.

• Avoid application to healthy skin, open wounds, or infected areas.
• Do not use under occlusive dressings unless directed by a healthcare professional.
• Limit treatment duration as advised; prolonged use may increase risk of skin atrophy.
• Use caution in patients with a history of hypersensitivity to corticosteroids or vitamin D analogs.
• Not recommended for use on the face, intertriginous zones, or mucous membranes unless specifically prescribed.
• Pregnant or breastfeeding women should consult a physician, as safety data are limited.

Enstilar may interact with certain topical or systemic agents; awareness helps prevent reduced efficacy or increased toxicity.

Avoid

• Concurrent use with other potent topical corticosteroids on the same area, which can amplify systemic absorption.
• Application together with topical calcineurin inhibitors, as combined immunosuppression may increase infection risk.

Use with caution

• Systemic vitamin D analogs or calcium supplements, which could raise serum calcium levels.
• Antifungal or antibacterial creams applied to the same site, potentially altering drug absorption.
• Phototherapy (UVB) performed on treated skin, as corticosteroids may reduce phototherapeutic response.